A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
- Conditions
- Advanced Non Small Cell Lung CancerAdvanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05318573
- Locations
- 🇺🇸
Cancer and Blood Speciality Clinic, Long Beach, California, United States
🇺🇸Sharp Memorial Hospital (Oncology Clinical Research), San Diego, California, United States
🇺🇸Nebraska Cancer Specialists - Legacy, Omaha, Nebraska, United States
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04358549
- Locations
- 🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
- Conditions
- Merkel Cell CarcinomaAdvanced Solid Tumors
- Interventions
- Drug: FF-10850 Topotecan Liposome Injection
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04047251
- Locations
- 🇺🇸
Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Registration Number
- NCT03486353
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
- Conditions
- Biliary Tract CancerAdvanced Solid Tumors
- Interventions
- Drug: FF-10832 Gemcitabine Liposome Injection
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03440450
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Hoag Memorial Hospital Comprehensive Cancer Center, Newport Beach, California, United States
Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT03194685
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸University Of California, San Francisco School of Medicine, San Francisco, California, United States
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 99
- Registration Number
- NCT02661542
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT02454010
- Locations
- 🇺🇸
Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Northwestern University - Feinberg School of Medicine, Chicago, Illinois, United States
Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT02193958
- Locations
- 🇺🇸
Cleveland Clinic at Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States